Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D38LQO
|
|||
| Drug Name |
MW150
|
|||
| Synonyms |
MW-150; 1628502-91-9; 6-(4-Methylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)pyridazine; MW150; 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-pyridazine; EPZ68T461K; CHEMBL4129018; 6-(4-methylpiperazin-1-yl)-3-naphthalen-2-yl-4-pyridin-4-ylpyridazine; MW01-18-150SRM; MW 150; 6-(4-Methyl-piperazin-1-yl)-(2-naphthalen-2-yl)-4-pyridin-4-ylpyridazine; Pyridazine, 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-; UNII-EPZ68T461K; SCHEMBL16061104; EX-A3206A; GTPL10524; CIIVUDIZZJLXCN-UHFFFAOYSA-N; BDBM50537600; NSC785340; AKOS040758765; compound 8 [PMID: 25676389]; NSC-785340; compound 11 [PMID: 30978288]; compound 27 [WO2014145485A2]; MS-26255; HY-120111; CS-0069509; Q27453797; 3GF
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Company |
Neurokine Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H23N5
|
|||
| Canonical SMILES |
CN1CCN(CC1)C2=NN=C(C(=C2)C3=CC=NC=C3)C4=CC5=CC=CC=C5C=C4
|
|||
| InChI |
InChI=1S/C24H23N5/c1-28-12-14-29(15-13-28)23-17-22(19-8-10-25-11-9-19)24(27-26-23)21-7-6-18-4-2-3-5-20(18)16-21/h2-11,16-17H,12-15H2,1H3
|
|||
| InChIKey |
CIIVUDIZZJLXCN-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Stress-activated protein kinase (p38) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05194163) A Phase 2a Study of MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease. U.S.National Institutes of Health. | |||
| REF 2 | p38alpha MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10245-E10254. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.